Sort By: Newest first | Oldest first
AstraZeneca has failed to prevent generic companies from selling competing generic versions of its Crestor cholesterol drug. Minter Ellison represented Watson and Ascent in this matter.
Minter Ellison’s Paul Kallenbach has told the Australian Financial Review that many companies are not prepared for the biggest change in privacy laws in a quarter-century.
Minter Ellison has announced that two Australian intellectual property and patent and trademark litigators, and their team, have joined the firm.